18F-FDG PET/CT in the Evaluation of Solitary Extramedullary Plasmacytoma: A Case Series

Document Type : Case Series


1 Department of Nuclear Medicine, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, Gujarat, India

2 Department of Surgical Oncology, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad, Gujarat, India

3 Department of Radiation Oncology, Gujarat Cancer and Research Institute, Asarwa, Ahmedabad,Gujarat, India


The role of fluorine-18-fluorodeoxyglucose positron emission tomography/ computed tomography (18F-FDG PET/CT) in patients with multiple myeloma (MM) and other plasma cell disorders is well-known. Solitary plasmacytoma (SP), an extremely rare form within this entity accounting for approximately 4% of plasma cell malignancies, can be classified as solitary bone plasmacytoma (SBP) or solitary extramedullary plasmacytoma (SEMP). Extramedullary plasmacytoma (EMP) is a rare neoplasm characterized by the monoclonal proliferation of plasma cells outside the bone marrow. Breast and craniocerebral regions are the uncommon sites of the presentations of EMP, rarely reported in the literature. The most frequent site of presentation is the upper airways. The EMPs have similar pathogenesis as MM; however, they differ in management as they are radiosensitive in nature, and radiotherapy is the preferred treatment modality. As SEMP has a better prognosis than SPB with a lower conversion rate to MM, accurate staging is essential to plan for the treatment. The 18F-FDG PET/CT has higher sensitivity for the evaluation of treatment response. In the present case series, it was aimed to depict the role of 18F-FDG PET/CT in newly diagnosed SEMP with different sites of origin to exclude further lesions leading to changes in the treatment plan and treatment response assessment.


Main Subjects

1. Hillengass J, Usmani S, Rajkumar SV, Durie B G M , Mateos M V , Lonial S, et al. International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders. Lancet Oncol. 2019 Jun; 20(6):e302-e312.
2. Caers J, Paiva B, Zamagni E, Leleu X, Bladé J, Kristinsson S Y, et al. Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel. J Hematol Oncol. 2018; 11:10.
3. ahi H, Genell A, Walinder G, , Uttervall , Juliusson G , Karin F, et al. Incidence, characteristics,and outcome of solitary plasmacytoma and plasma cell leukemia. Population-based data from the Swedishmyeloma register. Eur J Haematol 2017; 99: 216–22.
4. Schridde H. Weitere Untersuchungen über die Kornelungen der Plasmazellen. Centralblatt Allg Pathologie 1905; 16:433–5.
5. Linqi Zhang, Xu Zhang, Qiao He, Rusen Zhang, Wei Fan. The role of initial 18F-FDG PET/CT in the management of patients with suspected extramedullary plasmocytoma. Cancer Imaging 2018; 18:19.
6. Blade J, Fernandez de Larrea C, Rosinol L. Extramedullary involvement in multiple myeloma. Haematologica 2012; 97: 1618-1619.
7. Thumallapally N, Meshref A, Mousa M, et al, Terjanian T. Solitary plasmacytoma: population-based analysis of survival trends and effect of various treatment modalities in the USA. BMC Cancer 2017; 17(1):13. 20 .
8. Krause S, Hillengass J, Goldschmidt H, Debus J, Neuhof D. Radiotherapy of solitary plasmacytoma. Ann Hematol. 2011; 90(9):1093–7.
9. Finsinger P, Grammatico S, Chisini M, Piciocchi A, Foà R, Petrucci MT. Clinical features and prognostic factors in solitary plasmacytoma. Br J Haematol. 2016; 172(4): 554–60.
10. 'Aguillo C, Soni RS, Gordhan C, Liu JK, Baredes S, Eloy JA. Sinonasal extramedullary plasmacytoma: a systematic review of 175 patients. Int Forum Allergy Rhinol. 2014; 4(2):156–63.
11. Gabriel U, Joseph U, Bassey IA, Joshua A, Emmanuel D. Plasmacytoma of the Breast: A Report of a Rare Disease. Ethiop J Health Sci 2015; 25(4):373-6.
12. Fischer TR da C, Higashi F, Crusoe E de Q, VT de M. Bilateral Breast Plasmacytoma: A Clinical Case Report. Rev Bras Hematol Hemoter. 2016; 38(2):166-9.
13. Khalili RP, Mokhtari M, Norouzi R. Solitary dural plasmacytoma with parenchymal invasion. Asian J Neurosurg. 2015; 10(2)102-104.
14. T. M. Anoop TM, Jain N, and Nair SG. Intracranial plasmacytoma mimicking meningioma. J Neurosci Rural Pract. 2014; 5(1): 87.
15. Dong A, Wang Y, Lu JP, Zuo C. Spectrum of breast lesions with increased F18-FDG uptake on PET-CT. Clinical Nuclear Medicine 2016(41); 543-557.
16. Ching AS, Khoo JB, Chong VF. CT and MR imaging of solitary extramedullary plasmacytoma of the nasal tract. AJNR Am J Neuroradiol. 2002; 23(10):1632–6
17. Cantone E, Di Lullo AM, Marano L, Guadagno E , Mansueto G , Capriglione P, et al. Strategy for the treatment and follow-up of sinonasal solitary extramedullary plasmacytoma: A case series. J Med Case Rep. 2017; 11(1):219
18. Wen G, Wang W, Zhang Y, Niu S, Li Q, Li Y et al. Management of extramedullary plasmacytoma: Role of radiotherapy and prognostic factor analysis is in 55 patients. Chin J CancerRes. 2017;29(5):438–46
19. Taheri A, Shamsaei H, Sharouny H. Extramedullary Plasmacytoma of the Maxillary Sinus with Intra-Orbital Extension: A Case Report of a Rare Condition Rep Radiother Oncol. 2018; 5(1):e82423.